NASA Artemis II: First Crewed Moon Mission Since Apollo Takes Four Astronauts on 10-Day Lunar Journey 
Tabletop particle accelerator could transform medicine and materials science 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
RFK Jr. Expands CDC Vaccine Advisory Panel's Scope Amid Legal Battles 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Asian Currencies Stay Range-Bound as Dollar Holds Steady Ahead of Fed Nominee Hearing 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman 
Canada-USMCA Review 2026: No Collapse Expected Despite July 1 Deadline 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Gold Prices Drop as Oil Rally and U.S.-Iran Tensions Shake Markets 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
The four types of dementia most people don’t know exist 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
